Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring (Jan 2020)

Amyloid duration is associated with preclinical cognitive decline and tau PET

  • Rebecca L. Koscik,
  • Tobey J. Betthauser,
  • Erin M. Jonaitis,
  • Samantha L. Allison,
  • Lindsay R. Clark,
  • Bruce P. Hermann,
  • Karly A. Cody,
  • Jonathan W. Engle,
  • Todd E. Barnhart,
  • Charles K. Stone,
  • Nathaniel A. Chin,
  • Cynthia M. Carlsson,
  • Sanjay Asthana,
  • Bradley T. Christian,
  • Sterling C. Johnson

DOI
https://doi.org/10.1002/dad2.12007
Journal volume & issue
Vol. 12, no. 1
pp. n/a – n/a

Abstract

Read online

Abstract Introduction This study applies a novel algorithm to longitudinal amyloid positron emission tomography (PET) imaging to identify age‐heterogeneous amyloid trajectory groups, estimate the age and duration (chronicity) of amyloid positivity, and investigate chronicity in relation to cognitive decline and tau burden. Methods Cognitively unimpaired participants (n = 257) underwent one to four amyloid PET scans (Pittsburgh Compound B, PiB). Group‐based trajectory modeling was applied to participants with longitudinal scans (n = 171) to identify and model amyloid trajectory groups, which were combined with Bayes theorem to estimate age and chronicity of amyloid positivity. Relationships between chronicity, cognition, clinical progression, and tau PET (MK‐6240) were investigated using regression models. Results Chronicity explained more heterogeneity in amyloid burden than age and binary amyloid status. Chronicity was associated with faster cognitive decline, increased risk of abnormal cognition, and higher entorhinal tau. Discussion Amyloid chronicity provides unique information about cognitive decline and neurofibrillary tangle development and may be useful to investigate preclinical Alzheimer's disease.

Keywords